声频共振联合全身激素及常规药物治疗突发性聋的随机对照研究

A randomized controlled clinical trial of acoustic resonance combined with systemic steroid therapy for sudden hearing loss

目的:探讨声频共振联合全身应用激素及常规药物治疗突发性聋(SHL)的近期及远期疗效。方法:将128例SHL患者随机分为对照组(60例)和声频组(68例)。对照组予以全身激素及常规药物治疗;声频组在对照组治疗的基础上,予以声频共振联合外耳道灌注药物(VitB1、VitB12、ATP)治疗。结果:治疗后2周,声频组总有效率为66.18%,对照组为65.00%;治疗后4周,声频组为72.06%,对照组为70.00%;治疗后8周,声频组为73.53%,对照组为68.33%。3个时期2组差异无统计学意义(P>0.05)。治疗后4周和8周,声频组平均听阈分别为(43.87±16.73)dB和(40.96±17.11)dB,明显低于对照组(50.89±18.41)dB、(48.93±17.84)dB(P<0.05)。治疗中均未出现严重不良事件。结论:应用激素及常规药物治疗可明显降低SHL患者听阈,且安全无明显不良反应,值得临床推广。

Objective：To study the short-term and long-term therapeutic effect of acoustic resonance combined with systemic steroid therapy in treatment of Sudden hearing loss（SHL）. Method：Clinical data of 128 patients with SHL were analyzed in the randomized controlled trial. Patients were divided into study group（68 cases） and con- trol group（60 cases）. Patients in control group received steroid therapy and conventional drug therapy, while study group received acoustic resonance therapy combined with systemic steroid therapy and conventional drug therapy. Result：The total effective rate of study group and control group was 66.18% and 65.00% respectively at the end of treatment; the total effective rate of study group and control group was 72.06% and 70.00% 4 weeks after treatment; the total efficiency of study group and control group was 73. 53% and 68. 33% respectively 8 weeks after treatment. The total effective rate of study group was not significantly higher than that of the control group in the three periods （P〉0.05）. But the PTA significantly improved in study group 4 weeks and 8 weeks after treatment E（43.87±16.73）dB, （40. 96±17. 11）dB2,while the PTA of control group is（50.89±18.41）dB, （48.93±17.84）dB（P〈0. 05）,and no serious adverse events were happened during treatments and after treatments. Conclusion：acoustic resonance combined with systemic steroid therapy can significantly improve the thera- peutic effect of SHL with no obvious side effects, which is worth clinical promotion.